在不稳定的心痛中,通过6-甲基普雷迪尼索隆调节阿司匹林不敏感的eicosanoid生物合成
Francesco Cipollone1, Antonina Ganci, Anita Greco
1Department of Medicine and Aging, University of Chieti G. D'Annunzio School of Medicine, Chieti, Italy. fcipollone@unich.it
Circulation
|January 8, 2003
概括
葡萄糖皮质体治疗降低了不稳定胸痛患者的白血C4 (LT C4) 生产,这表明炎症.
科学领域:
- 心脏病学 心脏病学
- 炎症研究 炎症研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症与急性冠状动脉综合征有关.
- 在不稳定的心痛中研究了炎症调解剂.
研究的目的:
- 在不稳定的心痛中研究葡萄糖皮质体对白血C4 (LT C4) 和血栓素A2 (TX A2) 生物合成的影响.
- 探索炎症在不稳定性胸痛病理生理学中的作用.
主要方法:
- 在不稳定心痛,稳定心痛和非血性胸痛患者的尿路LTE4和11-dehydro-TXB2进行比较.
- 静脉注射6-甲基prednisolone (6-MP) 或安慰剂给不稳定的胸痛患者.
- 在治疗前和治疗期间采集尿样,以测量eicosanoid分泌量.
主要成果:
- 在不稳定的胸痛患者中,尿液LTE4和11-dehydro-TXB2的水平升高.
- 在不稳定的胸痛患者中,6-MP显著降低了LTE4分泌.
- 在6MP治疗后,11-脱-TXB2水平没有显著变化.
结论:
- 血管活性白血素 (LT) 和血栓素 (TX) 可能在不稳定的心痛中过度产生的.
- 葡萄糖皮质类药物可以短期抑制LT C4生物合成.
- 葡萄糖皮质类药物可能有助于阐明炎症细胞激活在不稳定的心痛中的作用.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Angina II: Classification
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...


